Correction: Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway

Renxian Wang; WeiFeng Liu; Qian Wang; Guangping Li; Ben Wan; Yuyang Sun; Xiaohui Niu; Dafu Chen; Wei Tian

doi:10.1039/d1bm90066h

Correction: Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway

Biomater Sci. 2021 Jul 27;9(15):5383-5384. doi: 10.1039/d1bm90066h.

Authors

Renxian Wang¹, WeiFeng Liu², Qian Wang¹, Guangping Li¹, Ben Wan¹, Yuyang Sun¹, Xiaohui Niu², Dafu Chen¹, Wei Tian³

Affiliations

¹ Laboratory of Bone Tissue Engineering, Beijing Laboratory of Biomedical Materials, Beijing Research Institute of Traumatology and Orthopaedics, Beijing Jishuitan Hospital, Beijing 100035, China. chendafujst@126.com.
² Depatment of Orthopaedic Oncology Surgery, Beijing JiShuiTan Hospital, Peking Universit, Beijing 100035, China. niuxiaohui@263.net.
³ Department of Spine Surgery, Beijing JiShuiTan Hospital, Peking University, Beijing 100035, China.

PMID: 34236351
DOI: 10.1039/d1bm90066h

Abstract

Correction for 'Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway' by Renxian Wang et al., Biomater. Sci., 2020, 8, 4426-4437, DOI: 10.1039/D0BM00898B.

Publication types

Published Erratum